Subscribe

Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT)

USD2.43 -0.12 (-4.71%)
US NASDAQ Healthcare Biotechnology
Address 8031 Cooper Creek Blvd., Unit 103 34201
University Park, FL, US
CEO Kelvin Cooper
IPO 2026-04-23
CIK 2079272 ISIN US51255A2015

Explore sections of this company profile

Description

This biopharmaceutical company is dedicated to developing innovative antimicrobial therapies. Its array of anti-infective products is designed to tackle specific viral conditions, including avian influenza, Epstein-Barr Virus (EBV), and hepatitis B and C. Established by Roderic Dale on July 11, 2006, the firm maintains its principal office in Bradenton, Florida.

News Sentiment (7d)
Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
USD2.43 -0.12 (-4.71%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
286.3K
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-7.52% +1.50% -74.62% -92.20% -92.20% -92.20% -92.20% -92.20% -92.20% -92.20% -92.20%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial statements will be available after the next weekly refresh.
Valuation data will be available after the next weekly refresh.
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-28 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
Ownership data is not available for this company yet.

Executive team

Top executives
Shares Outstanding
4.69M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings
Filing date Form type Filing
2026-05-26 424B3
2026-05-26 424B3
2026-05-22 10-Q
2026-05-14 424B4
2026-05-13 EFFECT
2026-05-06 4
2026-05-06 3
2026-05-01 S-1
2026-05-01 3
2026-05-01 3

Executive team

NameTitleCompensationGender
Kelvin Cooper CEO, SVP of Research & Development and Director 190.4K
Thomas Balzer Chief Medical Officer & SVP of Clinical Development 177.9K
Peter F. Ceccacci CFO & VP of Administration 160.0K male
Daniel Kontoh-Boateng Investor Relations
Tara Endress Project Manager & Accounting Manager female
ESG Rating
E (Environmental)
48.1
S (Social)
69.7
G (Governance)
62.6
ESG Total
60.1
ESG Score History
Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings reports

Stock splits